Get these analyses to your inbox — https://axialdeck.substack.com/ This is a newsletter to review public company presentations in life sciences. More well thought out work can be found at — https://axial.substack.com/ I figured that there is a diversity across desire for frequency of emails.
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
Nevro is a medical device company that has brought their spinal cord stimulation (SCS) to patients suffering from chronic pain. Its Senza system powers Nevro’s HF10 therapy using neuromodulation to clinically show long-term pain relief: https://www.hf10.com/why-hf10/overview/ The product is pretty amazing and Nevro is on the precipice of building a durable business model. Device companies are really hard to get started, but in the long-run, the moats are pretty powerful: there’s really no such thing as a generic medical device.
Founded in 2006, Nevro got backing from Johnson & Johnson, Novo Nordisk, and Covidien and went public in 2014. It took Nevro 9 years from founding to get their product approved in 2015 originally for patients with chronic intractable pain of the trunk or limbs. With the SCS market generating $1B-$2B in revenue per year, Nevro has been able to gain over 15% of the market in ~5 years.
